This multi-receptor mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist), and has been associated with pronounced reductions in body weight and improvements in metabolic parameters in early clinical studies
Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis, Cureus (2023) The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists, Diabetes, Obesity, and Metabolism (2020) What is the incidence of pancreatitis associated with Zepbound (tirzepatide)?, Eli Lilly website (2024) Constipation and impaction, Harvard Health (2023) Pancreatitis, Johns Hopkins Medicine (2025) Gallstones and gallbladder disease, Mount Sinai Zepbound label, Food and Drug Administration (2025) Gingers nutritional implication on gastrointestinal health, Clinical Nutrition Open Science (2025) Review article: The physiologic effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders, Alimentary Pharmacology and Therapeutics (2018) Efficacy and safety of peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome, Gastroenterology (2020) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
PlexusDx works with licensed compounding pharmacies and recommends a thorough medical review before any GLP-1 therapy begins
In Thornton, Zepbound may be exactly what you need to overcome the hurdle of constant hunger while supporting a calorie deficit lifestyle
It is typically mild at the starting dose and improves within the first week as your body adjusts to the medication
